BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28341732)

  • 1. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
    Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
    Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
    Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
    Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.
    Bochtler T; Hegenbart U; Cremer FW; Heiss C; Benner A; Hose D; Moos M; Bila J; Bartram CR; Ho AD; Goldschmidt H; Jauch A; Schonland SO
    Blood; 2008 May; 111(9):4700-5. PubMed ID: 18305218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis.
    Harrison CJ; Mazzullo H; Ross FM; Cheung KL; Gerrard G; Harewood L; Mehta A; Lachmann HJ; Hawkins PN; Orchard KH
    Br J Haematol; 2002 May; 117(2):427-35. PubMed ID: 11972529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.
    Bochtler T; Hegenbart U; Kunz C; Benner A; Kimmich C; Seckinger A; Hose D; Goldschmidt H; Granzow M; Dreger P; Ho AD; Jauch A; Schönland SO
    Blood; 2016 Jul; 128(4):594-602. PubMed ID: 27257181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
    Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
    Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
    Bochtler T; Hegenbart U; Kunz C; Benner A; Seckinger A; Dietrich S; Granzow M; Neben K; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    Amyloid; 2014 Mar; 21(1):9-17. PubMed ID: 24455967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations.
    Sander S; Bullinger L; Leupolt E; Benner A; Kienle D; Katzenberger T; Kalla J; Ott G; Müller-Hermelink HK; Barth TF; Möller P; Lichter P; Döhner H; Stilgenbauer S
    Haematologica; 2008 May; 93(5):680-7. PubMed ID: 18367489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.
    Hayman SR; Bailey RJ; Jalal SM; Ahmann GJ; Dispenzieri A; Gertz MA; Greipp PR; Kyle RA; Lacy MQ; Rajkumar SV; Witzig TE; Lust JA; Fonseca R
    Blood; 2001 Oct; 98(7):2266-8. PubMed ID: 11568015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.
    Muchtar E; Dispenzieri A; Kumar SK; Ketterling RP; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA
    Leukemia; 2017 Jul; 31(7):1562-1569. PubMed ID: 27904139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
    J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
    Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
    Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis.
    Döhner H; Stilgenbauer S; Döhner K; Bentz M; Lichter P
    J Mol Med (Berl); 1999 Feb; 77(2):266-81. PubMed ID: 10023780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
    Fonseca R; Blood E; Rue M; Harrington D; Oken MM; Kyle RA; Dewald GW; Van Ness B; Van Wier SA; Henderson KJ; Bailey RJ; Greipp PR
    Blood; 2003 Jun; 101(11):4569-75. PubMed ID: 12576322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
    Bryce AH; Ketterling RP; Gertz MA; Lacy M; Knudson RA; Zeldenrust S; Kumar S; Hayman S; Buadi F; Kyle RA; Greipp PR; Lust JA; Russell S; Rajkumar SV; Fonseca R; Dispenzieri A
    Haematologica; 2009 Mar; 94(3):380-6. PubMed ID: 19211640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.
    Cremer FW; Bila J; Buck I; Kartal M; Hose D; Ittrich C; Benner A; Raab MS; Theil AC; Moos M; Goldschmidt H; Bartram CR; Jauch A
    Genes Chromosomes Cancer; 2005 Oct; 44(2):194-203. PubMed ID: 16001433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma.
    Dalmasso C; Carpentier W; Guettier C; Camilleri-Broët S; Borelli WV; Campos Dos Santos CR; Castaing D; Duclos-Vallée JC; Broët P
    BMC Cancer; 2015 Mar; 15():126. PubMed ID: 25879652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.